English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The objective of present study was to develop solid self-microemulsifying drug delivery system (SMEDDS) for improving the delivery of a BCS class II antidiabetic agent pioglitazone HCL and evaluated by in-vitro, and in-vivo techniques. Screening of excipients was done by determining the equilibrium solubility of pioglitazone HCL in different oils, surfactants and cosurfactants, pioglitazone HCL showed highest solubility in coconut oil (oil), Tween 80 (surfactant), PEG 400 (Co-surfactant) and phase diagram was constructed to identify the self-microemulsification region. Liquid SMEDDS was prepared and was converted to S-SMEDDS by spray-drying of the liquid SMEDDS in a laboratory spray dryer using aerosil 200 as solid carrier. Solid state characterization of the solid SMEDDS was performed by SEM, DSC and X-ray powder diffraction. The optimized system possessed a mean globule size of 201.2 nm, PDI 0.457 and Zeta potential -0.975 mV. The prepared S-SMEDDS was filled in hard gelatin capsule shell size „0‟ and in-vitro dissolution study were performed, from dissolution study it was concluded that S-SMEDDS form of showed complete and faster dissolution as compared to marketed formulation of pioglitazone HCL (piosys 15 tablet). In-vivo performance of SSMEDDS was evaluated in Wistar rat using plasma glucose level was determined by oral glucose tolerance test. The test formulation (1:1 C) showed significant reduction in plasma glucose level, after oral administration. A one month stability studies were performed (40 0 C & 75% RH) showed no change in physical appearance and dissolution rate of the drug.

journal of current pharma research

A Novel solid-self microemulsifying drug delivery system of Pioglitazone Hydrochloride: Formulation, Development and Characterization by in vitro and in vivo techniques.